ATE552855T1 - Kombinationen und zubereitung zur anwendung in pdt zur behandlung von augenleiden mit unerwünschter choriodaler neovascularisation - Google Patents

Kombinationen und zubereitung zur anwendung in pdt zur behandlung von augenleiden mit unerwünschter choriodaler neovascularisation

Info

Publication number
ATE552855T1
ATE552855T1 AT08001574T AT08001574T ATE552855T1 AT E552855 T1 ATE552855 T1 AT E552855T1 AT 08001574 T AT08001574 T AT 08001574T AT 08001574 T AT08001574 T AT 08001574T AT E552855 T1 ATE552855 T1 AT E552855T1
Authority
AT
Austria
Prior art keywords
pdt
undesirable
combinations
preparation
treatment
Prior art date
Application number
AT08001574T
Other languages
English (en)
Inventor
Joan W Miller
Evangalos S Gragoudas
Reem Z Renno
Original Assignee
Massachusetts Eye & Ear Infirm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirm filed Critical Massachusetts Eye & Ear Infirm
Application granted granted Critical
Publication of ATE552855T1 publication Critical patent/ATE552855T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
AT08001574T 2000-02-10 2001-02-09 Kombinationen und zubereitung zur anwendung in pdt zur behandlung von augenleiden mit unerwünschter choriodaler neovascularisation ATE552855T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18164100P 2000-02-10 2000-02-10

Publications (1)

Publication Number Publication Date
ATE552855T1 true ATE552855T1 (de) 2012-04-15

Family

ID=22665146

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01907170T ATE406914T1 (de) 2000-02-10 2001-02-09 Photodynamische therapie zur behandlung von augenerkrankungen
AT08001574T ATE552855T1 (de) 2000-02-10 2001-02-09 Kombinationen und zubereitung zur anwendung in pdt zur behandlung von augenleiden mit unerwünschter choriodaler neovascularisation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01907170T ATE406914T1 (de) 2000-02-10 2001-02-09 Photodynamische therapie zur behandlung von augenerkrankungen

Country Status (9)

Country Link
US (7) US7125542B2 (de)
EP (2) EP1253943B1 (de)
JP (3) JP2003530146A (de)
AT (2) ATE406914T1 (de)
AU (2) AU3497901A (de)
CA (2) CA2398901C (de)
DE (1) DE60135633D1 (de)
ES (1) ES2311507T3 (de)
WO (1) WO2001058240A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CA2403612A1 (en) * 2000-03-24 2001-10-11 Romulus Kimbro Brazzell Improved treatment of neovascularization
EP1570859A3 (de) * 2000-03-24 2008-04-02 Novartis AG Verbesserte Behandlung von Neovaskularisation
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
WO2002062384A2 (en) * 2001-02-06 2002-08-15 Qlt Inc. Reduced fluence rate pdt
US6875165B2 (en) * 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
AU2002240463A1 (en) * 2001-02-22 2002-09-12 Novartis Ag Use of endostatin in the treatment of ocular neovascularization
CA2445898A1 (en) * 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
PT1423115E (pt) * 2001-08-06 2009-07-21 Childrens Medical Center Actividade antiangiogénica de análogos da talidomida substituídos com nitrogénio
GEP20063755B (en) * 2001-11-09 2006-02-27 Eyetech Pharmaceuticals Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
AU2003209297A1 (en) * 2002-01-18 2003-09-02 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
AU2003299201A1 (en) 2002-10-03 2004-04-23 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
US20050043220A1 (en) * 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
EP1606301A4 (de) * 2003-01-21 2006-06-14 Archemix Corp Aptamer-therapeutika zur arzneimitteltherapie für augen
EP1605847B1 (de) * 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Gegen antikörper gerichtete photodynamische therapie
US20070020272A1 (en) * 2003-04-30 2007-01-25 Tayyaba Hasan Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
ATE488269T1 (de) * 2004-02-12 2010-12-15 Neovista Inc Gerät für die intraokulare brachytherapie
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
US7803375B2 (en) * 2005-02-23 2010-09-28 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
BRPI0618677A2 (pt) 2005-11-15 2011-09-06 Neovista Inc métodos e aparelho para braquiterapia intra-ocular
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US10259860B2 (en) * 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
US8480662B2 (en) * 2007-08-22 2013-07-09 Cardiac Pacemakers, Inc. Systems and devices for photoablation
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
US8353812B2 (en) 2008-06-04 2013-01-15 Neovista, Inc. Handheld radiation delivery system
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
US8530189B2 (en) * 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
WO2010129775A1 (en) 2009-05-06 2010-11-11 University Of Virginia Patent Foundation Self-illuminated handheld lens for retinal examination and photography and related method thereof
MX361709B (es) 2009-11-09 2018-12-07 Allergan Inc Composiciones y metodos para estimular el crecimiento del cabello.
EP2576786B1 (de) * 2010-05-27 2016-04-06 The University of Hong Kong Hochaffine nukleinsäure-aptamere gegen das sclerostin-protein
JP5609273B2 (ja) * 2010-06-01 2014-10-22 国立大学法人 東京大学 血小板解析方法及び血小板解析システム
EP2665481B1 (de) 2011-01-19 2016-03-30 Topokine Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung des stoffwechselsyndroms
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2014081941A1 (en) 2012-11-21 2014-05-30 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
WO2014127243A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
NO2753788T3 (de) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
US10314473B2 (en) * 2015-09-09 2019-06-11 New York University System and method for in vivo detection of fluorescence from an eye
US20190022220A1 (en) * 2016-01-30 2019-01-24 The Board Of Trustees Of The Leland Stanford Junior University Light-activated anchoring of therapeutic factors to tissues
US10750943B2 (en) 2017-06-09 2020-08-25 Northwestern University Imaging-guided creating and monitoring of retinal vascular occlusive disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US49247A (en) * 1865-08-08 Improvement in the manufacture of pyroligneous acid
US43220A (en) * 1864-06-21 Improved evaporating-pan for sugar-and sirup
US171320A (en) * 1875-12-21 Improvement in horseshoe-machines
US167091A (en) * 1875-08-24 Improvement in swinging berths for ships
US5283255A (en) 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5214036A (en) 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
DE4322409C2 (de) * 1993-07-06 2003-12-04 Beck August Gmbh Co Vorrichtung zur zerspanenden Bearbeitung
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5707986A (en) * 1994-03-14 1998-01-13 Miller; Joan W. Angiographic method using green porphyrins in primate eyes
AU6813694A (en) * 1994-03-14 1995-10-03 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CN1636594B (zh) 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6008211A (en) 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5707608A (en) 1995-08-02 1998-01-13 Qlt Phototherapeutics, Inc. Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
ES2169864T3 (es) 1996-05-31 2002-07-16 Health Research Inc Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis.
US6180402B1 (en) * 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
JP2002512594A (ja) * 1996-12-11 2002-04-23 ファーマサイクリックス，インコーポレイテッド 眼の診断および治療におけるテキサフィリンの使用
US6270749B1 (en) * 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
GB9700396D0 (en) * 1997-01-10 1997-02-26 Photocure As Photochemotherapeutic compositions
CN1252006A (zh) * 1997-03-10 2000-05-03 研究发展基金会 用光动力学治疗产生的氧化应激来暂时性、选择性表达异源基因
US6331523B1 (en) * 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
RU2229305C2 (ru) 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
EP1077944A1 (de) * 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide verbindungen,methode und zusammensetzungen zur hemmung derparp-aktivitaet
WO1999060984A2 (en) * 1998-05-22 1999-12-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
JP2002534139A (ja) 1999-01-05 2002-10-15 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜と脈絡膜への経強膜徐放性薬剤標的送達
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6162242A (en) * 1999-01-21 2000-12-19 Peyman; Gholam A. Selective photodynamic treatment
WO2000051638A1 (en) * 1999-02-26 2000-09-08 Qlt Phototherapeutics Inc. Photodynamic therapy in combination with apoptosis inducing factors
US6887468B1 (en) * 1999-04-28 2005-05-03 Board Of Regents, The University Of Texas System Antibody kits for selectively inhibiting VEGF
US6443976B1 (en) * 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
JP2003519670A (ja) 2000-01-12 2003-06-24 ライト サイエンシーズ コーポレイション 眼疾患の新規処置
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
GEP20063755B (en) 2001-11-09 2006-02-27 Eyetech Pharmaceuticals Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
US20050043220A1 (en) 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
US7803375B2 (en) * 2005-02-23 2010-09-28 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye

Also Published As

Publication number Publication date
US20020040015A1 (en) 2002-04-04
US20120323162A1 (en) 2012-12-20
WO2001058240A2 (en) 2001-08-16
EP1253943A2 (de) 2002-11-06
DE60135633D1 (de) 2008-10-16
CA2714081C (en) 2013-08-06
ATE406914T1 (de) 2008-09-15
US20090286743A1 (en) 2009-11-19
JP2010065057A (ja) 2010-03-25
US20030185834A1 (en) 2003-10-02
CA2398901C (en) 2010-11-16
JP5749750B2 (ja) 2015-07-15
AU2001234979B2 (en) 2006-07-27
EP1253943B1 (de) 2008-09-03
EP1997513B1 (de) 2012-04-11
AU3497901A (en) 2001-08-20
WO2001058240A3 (en) 2002-04-11
US7125542B2 (en) 2006-10-24
EP1997513A1 (de) 2008-12-03
US20030175282A1 (en) 2003-09-18
JP2003530146A (ja) 2003-10-14
US20110144035A1 (en) 2011-06-16
ES2311507T3 (es) 2009-02-16
CA2714081A1 (en) 2001-08-16
JP2013082746A (ja) 2013-05-09
CA2398901A1 (en) 2001-08-16
US20140163451A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
ATE552855T1 (de) Kombinationen und zubereitung zur anwendung in pdt zur behandlung von augenleiden mit unerwünschter choriodaler neovascularisation
ATE426413T1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
WO2001039764A3 (en) Methods for treating conditions and illnesses associated with abnormal vasculature
EA200702267A1 (ru) Терапевтическая контактная линза для псевдо-афакических глаз и/или глаз, подверженных нейродегенеративному процессу
WO2007097839A3 (en) Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
MX2011006376A (es) Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable.
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
ATE554763T1 (de) Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation
WO2006091666A3 (en) Methods and compositions for treating conditions of the eye
BR0213975A (pt) Métodos para tratar doenças neovasculares oculares
GB2442915B (en) Perylenequinone derivatives and uses thereof
ZA202109122B (en) A process for the manufacturing of (6ar,10ar)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinoline and (4ar,10ar)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol
WO2006020979A3 (en) Factor vii conjugates for selectively treating neovascularization disorders
NO20024486D0 (no) Forbedret behandling av neovaskularisering
EA200700772A1 (ru) Аналоги полиаминов в качестве терапевтических средств для глазных заболеваний
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
Kessel Thomas J. Dougherty: An Appreciation
Maftoum‐Costa et al. Mitochondria, endoplasmic reticulum and actin filament behavior after PDT with chloroaluminum phthalocyanine liposomal in HeLa cells
BRPI0410875A (pt) método de inibição do crescimento de tumor com anticorpos de fator antitecido
DE69912304D1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
WO2003006002A8 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
ATE466835T1 (de) Aliphatisch substituierte demethoxylierte hypocrelline und deren herstellung
DE50106329D1 (de) Photodynamische behandlung und uv-b- bestrahlung einer thrombozyten-suspension
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen